Trial · NCT03910439
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 12 of 12
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine aminotransferase increased | Investigations | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 3 |
| other | Alkaline phosphatase increased | Investigations | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 1 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 1 |
| other | Aspartate aminotransferase increased | Investigations | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 2 |
| other | Chest pain - cardiac | Musculoskeletal and connective tissue disorders | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 1 |
| other | Eye disorders - Other, posterior vitreous detachment | Eye disorders | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 1 |
| other | Nausea | Gastrointestinal disorders | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 1 |
| other | Pain | General disorders | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 2 |
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 1 |
| other | Skin infection | Infections and infestations | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 2 |
| other | Syncope | Nervous system disorders | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 1 |
| other | Vomiting | Gastrointestinal disorders | 1/Avelumab 800 mg Intravenous (IV) Every Two Weeks in Combination With Radiation Therapy | 1 | 4 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03910439/events